The second ADC, SGN-CD19A (Seattle Genetics), comprises a humanized anti-CD19 monoclonal antibody ... unconfirmed; DLBCL: Diffuse large B.cell lymphoma; FL: Follicular lymphoma; HDT.SCT: High ...

This study presents a valuable finding on the direct cytotoxic effects of DuoHexaBody-CD37 in diffuse large B-cell lymphoma, mediated via SHP-1 activation and antibody clustering, independent of ...

In a Phase 1b/2a trial for lymphoma and cytokine release syndrome, the first group's dose-limiting toxicity observation ...

Like a creature from a science fiction movie, chronic lymphocytic leukemia (CLL) can be a shape-shifter. In a small number of ...

"Forty-one study patients (38 with diffuse large B-cell lymphoma (DLBCL ... and also tended to receive higher doses of CAR-positive cells, leading to earlier fevers compared to those with milder ...

Roche’s Columvi (glofitamab) has been approved by the European Commission (EC) as part of a combination treatment for diffuse large B-cell lymphoma (DLBCL ... The EC’s latest decision was supported by ...

The FDA approved Roche’s Columvi as a third-line treatment for a type of blood cancer called diffuse large B-cell lymphoma. This new Roche drug will compete against Epkinly, AbbVie’s recently ...

Diffuse large B-cell lymphoma (DLBCL) is the most common and fast-growing type of non-Hodgkin lymphoma, a cancer that affects ...

Two blood cancer treatments will now be available on the UK’s National Health Service (NHS) following recommendations from ...

Researchers recently concluded that the care received by patients treated by the Veterans Health Administration for diffuse large B-cell lymphoma met the standard of care across races and ...